The TRANSFORM study has launched in the UK to test how MRI could improve earlier detection of clinically significant prostate cancer and build evidence for broader screening decisions.
Prostate cancer is the most common cancer in UK men, but diagnosis still often depends on symptoms or GP visits, while PSA blood tests can miss early-stage or slow-growing disease.
MRI is already recommended by NICE as a first-line test for suspected localised prostate cancer because it can identify significant disease and reduce unnecessary biopsies.
NHS capacity remains a major constraint: the UK has fewer MRI scanners per capita than many comparable European countries, and workforce shortages limit scanning and reporting throughput.
The trial's wider significance is whether earlier diagnosis can be matched by investment in scanners, technology, staffing and public awareness, avoiding new bottlenecks as screening expands.